N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply
Lancet Respir Med
.
2017 Jan;5(1):e3.
doi: 10.1016/S2213-2600(16)30418-0.
Authors
Jürgen Behr
1
,
Bruno Crestani
2
,
Athol Wells
3
,
Klaus Kirchgaessler
4
,
Carlo Albera
5
Affiliations
1
University of Munich, Munich, Germany. Electronic address: juergen.behr@med.uni-muenchen.de.
2
Université Paris Diderot, Paris, France.
3
Royal Brompton Hospital, London, UK.
4
F Hoffmann-La Roche Ltd, Basel, Switzerland.
5
University of Turin, Turin, Italy.
PMID:
28000597
DOI:
10.1016/S2213-2600(16)30418-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Acetylcysteine*
Administration, Inhalation
Humans
Idiopathic Pulmonary Fibrosis*
Pulmonary Fibrosis
Vital Capacity
Substances
Acetylcysteine